Xeris Biopharma Holdings Forecast, price target & analysts
Xeris Biopharma Holdings Target price 2025 - Analyst rating & recommendation
Xeris Biopharma Holdings Classifications & Recommendation:
Xeris Biopharma Holdings Price Target
| Target Price | $9.69 |
| Price | $7.59 |
| Potential |
27.67%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Xeris Biopharma Holdings 2026 .
The average Xeris Biopharma Holdings target price is $9.69.
This is
27.67%
register free of charge
$11.55
52.17%
register free of charge
$6.06
20.16%
register free of charge
|
|
| A rating was issued by 12 analysts: 10 Analysts recommend Xeris Biopharma Holdings to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Xeris Biopharma Holdings stock has an average upside potential 2026 of
27.67%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 203.07 | 292.20 |
| 23.89% | 43.89% | |
| EBITDA Margin | -11.23% | 16.65% |
| 44.52% | 248.29% | |
| Net Margin | -27.01% | -1.41% |
| 28.90% | 94.78% |
8 Analysts have issued a sales forecast Xeris Biopharma Holdings 2025 . The average Xeris Biopharma Holdings sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Xeris Biopharma Holdings EBITDA forecast 2025. The average Xeris Biopharma Holdings EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Xeris Biopharma Holdings Analysts have issued a net profit forecast 2025. The average Xeris Biopharma Holdings net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.37 | -0.03 |
| 17.78% | 91.89% | |
| P/E | negative | |
| EV/Sales | 4.81 |
8 Analysts have issued a Xeris Biopharma Holdings forecast for earnings per share. The average Xeris Biopharma Holdings EPS is
This results in the following potential growth metrics and future valuations:
Xeris Biopharma Holdings...
Current Xeris Biopharma Holdings Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Oppenheimer |
Locked
➜
Locked
|
Locked | Oct 29 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | May 09 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Oct 29 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
May 09 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 11 2024 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 11 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
